---
title: "數碼健康初創 Hinge Health 美國 IPO 傳獲 15 倍超額認購 定價 32 美元"
description: "數碼物理治療初創公司 Hinge Health 在紐約證券交易所 IPO 定價為每股 32 美元，為招股價上限，並獲得 15 倍超額認購，該股上市股票代號為「HNGE」。公司透過出售 852 萬股股票籌集約 2.73 億美元。"
type: "news"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/news/241480476.md"
published_at: "2025-05-22T16:33:26.000Z"
---

# 數碼健康初創 Hinge Health 美國 IPO 傳獲 15 倍超額認購 定價 32 美元

> 數碼物理治療初創公司 Hinge Health 在紐約證券交易所 IPO 定價為每股 32 美元，為招股價上限，並獲得 15 倍超額認購，該股上市股票代號為「HNGE」。公司透過出售 852 萬股股票籌集約 2.73 億美元。

數碼物理治療初創公司 Hinge Health 在紐約證券交易所 IPO 定價為每股 32 美元，為招股價上限，並獲得 15 倍超額認購，該股上市股票代號為「HNGE」。

公司透過出售 852 萬股股票籌集約 2.73 億美元。

### Related Stocks

- [HNGE.US - Hinge Health](https://longbridge.com/zh-HK/quote/HNGE.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Breaking Down Hinge Health: 7 Analysts Share Their Views | Seven analysts have recently evaluated Hinge Health (NYSE:HNGE), providing a mix of bullish and bearish opinions. The av | [Link](https://longbridge.com/zh-HK/news/275600552.md) |
| Hinge Health CEO Daniel Perez Reports Disposal of Common Shares | Hinge Health CEO Daniel Perez has reported the disposal of common shares of Hinge Health Inc. The full filing is availab | [Link](https://longbridge.com/zh-HK/news/271703348.md) |
| US trading partners cheer Supreme Court tariff ruling — but businesses must still navigate 'murky waters' | The U.S. Supreme Court voted 6-3 to strike down large parts of President Trump's tariff policies Friday. | [Link](https://longbridge.com/zh-HK/news/276468032.md) |
| Cruise operator Carnival to unify dual listing | Carnivalannounced plans to unify its dual listings in New York and London and redomicile to Bermuda. The UK-listed Carni | [Link](https://longbridge.com/zh-HK/news/276491689.md) |
| Insider Selling: Atlassian (NASDAQ:TEAM) CTO Sells 3,072 Shares of Stock | Atlassian Corporation PLC CTO Rajeev Bashyam Rajan sold 3,072 shares of stock at an average price of $81.35, totaling $2 | [Link](https://longbridge.com/zh-HK/news/276497817.md) |

---

> **免責聲明**：本文內容僅供參考，不構成任何投資建議。